Abstract: Described herein are additive manufacturing methods and products made using such methods. The alloy compositions described herein are specifically selected for the additive manufacturing methods and provide products that exhibit superior mechanical properties as compared to their cast counterparts. Using the compositions and methods described herein, products that do not exhibit substantial coarsening, such as at elevated temperatures, can be obtained. The products further exhibit uniform microstructures along the print axis, thus contributing to improved strength and performance. Additives also can be used in the alloys described herein.

Abstract: Systems and methods for simulating and controlling a power system in real time, using a controller, are provided. The controller includes a simulation layer to simulate an operation of the power system, a disturbance generation layer to provide data to the simulation layer to disturb the simulated operation of the power system, an application layer to display the simulated operation of the power system and generate a control signal to control, based on the simulated operation of the power system, at least one element of the power system, and a distributed data streaming server (D2S2) to allow interoperability among the simulation layer, the disturbance layer, and the application layer.

Abstract: This invention is directed to selective androgen receptor degrader (SARD) compounds pharmaceutical compositions and uses thereof in treating early prostate cancer, prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.

Abstract: This invention is directed to pyrrole, pyrazole, imidazole, triazole, and morpholine based selective androgen receptor degrader (SARD) compounds including heterocyclic anilide rings and their synthetic precursors, R-isomers, and non-hydroxylated and/or non-chiral propanamides, and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.

Abstract: This invention is directed to pyrrole, pyrazole, imidazole, triazole, and morpholine based selective androgen receptor degrader (SARD) compounds including heterocyclic anilide rings and their synthetic precursors, R-isomers, and non-hydroxylated and/or non-chiral propanamides, and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.

Abstract: Described herein are additive manufacturing methods and products made using such methods. The alloy compositions described herein are specifically selected for the additive manufacturing methods and provide products that exhibit superior mechanical properties as compared to their cast counterparts. Using the compositions and methods described herein, products that do not exhibit substantial coarsening, such as at elevated temperatures, can be obtained. The products further exhibit uniform microstructures along the print axis, thus contributing to improved strength and performance. Additives also can be used in the alloys described herein.

Abstract: A method for the substantially complete conversion of hydrogenous matter to higher value product, the method comprising: (i) subjecting the hydrogenous matter to a substantially complete deconstruction process in which an aqueous phase containing a multiplicity of deconstructed compounds is produced; and (ii) contacting the aqueous phase with an anode of a microbial electrolysis cell, the anode containing a community of microbes thereon which oxidatively degrade one or more of the oxygenated organic compounds in the aqueous phase to produce protons and free electrons at the anode, wherein the protons and free electrons are transported to the cathode to produce hydrogen gas or a valuable reduced organic compound at the cathode upon application of a suitable cell potential across the anode and cathode. The invention is also directed to an apparatus for practicing the method described above.

Abstract: A method of thermally insulating a surface, the method comprising applying a coating of a thermally insulating composition onto said surface, wherein said thermally insulating composition comprises: (i) hollow spherical nanoparticles having a mean particle size of less than 800 nm in diameter and a particle size distribution in which at least 90% of the hollow spherical nanoparticles have a size within ±20% of said mean particle size, and a first layer of cationic or anionic molecules attached to said surfaces of the hollow spherical nanoparticles; and (ii) a second layer of molecules of opposite charge to the first layer of molecules, wherein said second layer of molecules of opposite charge are ionically associated with said first layer of molecules, wherein the molecules in said second layer have at least eight carbon atoms.

Abstract: Methods, apparatuses and systems for detecting tampering are disclosed. The methods, apparatuses and systems for detecting tampering can involve positioning at least a portion of one or more ingress/egress line having a first end and a second end in a clamping box configured to provide detection of tampering; and detecting tampering by observing the clamping box.

Abstract: Methods, apparatuses and systems for detecting tampering are disclosed. The methods, apparatuses and systems for detecting tampering can involve positioning at least a portion of one or more ingress/egress line having a first end and a second end in a clamping box configured to provide detection of tampering; and detecting tampering by observing the clamping box.

Abstract: An apparatus and method is described for a supplemental feeder system that provides a spring loaded supplemental feeder mounted on and spaced along a feed line. The spring loaded supplemental feeder acts as control that controls one or more follower supplemental feeders that is attached to control the one or more distally space apart supplemental feeders to dispense feed. The apparatus includes a pair of left and right annular collar clamps spaced apart and a tubular collar coaxial with respect to the left and right annular collar clamps and rotationally attached to the left and right annular collars. An extension tube having an interior extension channel is communicably attached to an interior channel of the tubular collar.

Abstract: Provided are methods and compositions to target delivery of cells to a tissue lesion, thereby treating the lesion. For example, biotinylated antibodies with affinity to a lesion epitope are administered at the lesion. Reparative cells including avidin and biotin are then administered at the lesion. The reparative cells are targeted to the lesion via avidin-biotin bridges to the antibodies, with additional cells recruited to the lesion via cell-to-cell avidin-biotin bridges. In certain examples, antibody-reparative cell complexes are formed by mixing the biotinylated antibodies with the reparative cells including avidin and biotin. The complexes are then administered at the lesion. In other examples, multivalent antibodies are used to target reparative cells to the lesion, such as by binding an epitope at the lesion and an epitope present on the reparative cell. In other examples, the antibodies are chemically linked to a reparative cell or to a nanosome containing a therapeutic agent.

Abstract: A molecule that binds specifically to a human tissue plasminogen activator (TPA) or a TPA mutant is provided. The molecule having sub-nanomolar affinity to inhibit fibrin-dependent plasminogen activation with an IC50<5 nM, to inhibit degradation of human fibron clots without affecting TPA amidolytic activity or non-fibrin-dependent activation, and the amino acid sequence of the TPA mutant is at least 65% identical to SEQ ID NO: 1 or SEQ ID NO: 2. Further provided is a method for treating systemic bleeding and brain hemorrhage after TPA treatment in a patient in need of such treatment. The method comprises administering to said patient an effective amount of the molecule, wherein the molecule selectively inhibits fibrin-augmented plasminogen activation in the patient.

Abstract: This invention provides substituted acylanilide compounds and uses thereof in treating a variety of diseases or conditions in a subject including, inter alia, a muscle wasting disease and/or disorder such as Duchenne muscular dystrophy or Becker muscular dystrophy.

Abstract: This invention is directed to pyrrole, pyrazole, imidazole, triazole, and morpholine based selective androgen receptor degrader (SARD) compounds including heterocyclic anilide rings and their synthetic precursors, R-isomers, and non-hydroxylated and/or non-chiral propanamides, and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.

Abstract: A transmitter for wireless power transfer is provided. The transmitter includes an input port, a first transmission port, a second transmission port, an inverter, and a controller. An input of the inverter is coupled to the input port, and an output of the inverter is coupled in parallel to the first and second transmission ports. The controller is programmed to control the inverter to modulate an output voltage at the output of the inverter such that power from the input port is transmitted at a first frequency through the first transmission port and at a second frequency through the second transmission port.

Abstract: The invention includes, in part, methods and apparatus for determining the status of labor in a pregnant subject. In some embodiments of the invention, organ-level uterine function is determined as a measure of the status of labor such as non-labor (e.g., false labor), latent phase labor, active phase labor, or post-delivery.

Abstract: Predicting gastrointestinal impairment may involve obtaining intestinal sounds of a patient to generate audio data, identifying predefined spectral events in the audio data that are predictive of subsequent gastrointestinal impairment, the spectral events being defined by predefined parameters, and predicting the likelihood of subsequent gastrointestinal impairment relative to the identified spectral events.

Abstract: This invention provides novel 3-amino propanamide selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, androgenic alopecia or other 5 hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.

Abstract: Embodiments of the present invention may provide a device for monitoring electric power at the distribution level. The device may include an analog-to-digital converter (ADC) to convert an input signal into digital samples at time intervals, a receiver to generate a pulse-per-second (PPS) signal, an oscillator to generate an oscillator signal, and a data processor coupled to the ADC, the receiver, and the oscillator. The data processor may include a counter to measure an oscillator frequency of the oscillator signal at each pulse of the PPS signal, an adjuster to adjust a timer period register value, and a timer to adjust the time intervals based on the adjusted timer period register value. Based on the digital samples, the data processor may generate a plurality of metrics, which may include one or more measurements of frequency, magnitude, phase, harmonic level, signal-to-noise ratio, sag, and swell of the input signal.